Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line

Eventide Asset Management trimmed 114,922 Mirum (MIRM) shares in Q3 but the position’s value rose by about $50.7M to $184.92M (2.52M shares) as of Sept. 30, making it the fund’s second-largest holding at ~3.04% of AUM. Mirum shares traded at $79.26 (up ~89% over the past year); the company reported Q3 revenue of $133M (+47% YoY), raised full-year guidance to $500–$510M, and held ~$378M in cash and investments, supporting near-term funding of its pipeline. The filing and metrics signal continued manager conviction amid price appreciation, reflecting portfolio rebalancing rather than a sell-off and reinforcing positive commercial momentum for Mirum’s liver-disease franchise.

Analysis

Market structure: Mirum (MIRM) moving from clinical to commercial changes demand dynamics — LIVMARLI’s ramp (Q3 revenue $133M, FY guide $500–510M) shifts value from binary trial outcomes to recurring prescription flow, benefiting specialty pharmacies, formulary-focused CROs and wholesalers while pressuring peers still pre-revenue. A $4.1B market cap with $378M cash reduces near-term dilution risk, making equity flows more about growth re-rating than financing; expect bid-side pressure into patent/reimbursement windows and elevated options IV around earnings and payer decisions.

Risk assessment: Tail risks include negative payer rulings or unexpected safety signals that could erase >40% market cap in weeks; regulatory denial on label expansion or failed pipeline readouts are low-probability, high-impact events. Near term (days–weeks) watch IV and volume into earnings; short-term (1–3 months) hinge on payer coverage updates and sales cadence; long-term (4–24 months) depends on international launches and additional indications. Hidden dependency: revenue durability depends on net price after rebates — public revenue growth masks potential margin compression if access is restricted.

Trade implications: Direct long exposure to MIRM is attractive but size carefully (1–2% NAV) because upside catalysts (pricing/coverage over next 3–6 months) are binary; prefer defined-risk options (9–12 month call spreads) or buying stock on pullbacks to $65–70. Relative trade: long MIRM vs short Guardant Health (GH) to capture dispersion between commercializing orphan-drug revenue vs diagnostic/biotech multiples; use 0.5–1% notional each. For volatility trades, sell 30–45 day covered calls after entry or buy calendar spreads if expecting subdued near-term moves but positive 2026 fundamentals.

Contrarian angles: The market may be underpricing reimbursement risk — consensus rewards revenue growth but underweights net price erosion; if payers grant broad coverage this underappreciated leverage could drive another 30–60% upside, but the reverse can prompt a >30% pullback. Historical parallels: BioMarin/Alexion launches saw rapid reratings then mid-cycle volatility when payers pushed back; Mirum’s multiple already reflects optimistic commercialization, so entry on confirmed two‑quarter repeatability of revenue (next 6 months) is prudent. Unintended consequence: heavy fund ownership (Eventide ~3% AUM) creates concentration risk — institutional selling to rebalance can pressure stock even without company weakness.

Key Decisions for Investors

• Establish a 1–2% long position in MIRM with a hard stop at 25% downside (~$59) and take-profit zones at $110 (≈+40%) and $150 (≈+90%), scale into any pullback to $65–70 within the next 3 months.
• Implement a defined-risk options trade: buy Jan 2026 80C / sell Jan 2026 120C call spread (ratio 1:1) sized to equal 0.5–1% portfolio exposure to capture upside through 2026 catalysts while capping cost.
• Run a pair trade: long MIRM (1% NAV) vs short GH (0.5% NAV) to exploit commercial-Rx vs diagnostic valuation divergence; rebalance after quarterly results or if GH announces positive guidance changes within 90 days.
• If you already own MIRM, monetize short-term IV by selling 30–60 day covered calls at ~10–15% OTM after establishing base position; avoid selling >50% of upside to preserve participation if payer outcomes surprise positively.
• Monitor three actionable triggers in the next 60–120 days before increasing size: (1) repeat quarterly growth meeting/raising FY guide, (2) a major payer (e.g., national PBM) broad formulary decision, and (3) any safety/regulatory update — each should be binary go/no-go for adding >0.5% more exposure.